Recent News

• 06.11.2026 - Penumbra’s THUNDERBOLT Receives FDA Clearance – Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
• 06.10.2026 - Q&A: Addressing Pelvic Venous Disease with a New Class of Coils
• 06.10.2026 - Q&A: Addressing Pelvic Venous Disease with a New Class of Coils
• 05.19.2026 - Improving Stroke Care Through Patient Advocacy:  A Q&A with Natalie Niekro, Penumbra’s Director of Patient Programs
• 05.13.2026 - Penumbra Partners with the National Blood Clot Alliance to Bring Blood Clot Education to Underserved Communities Across Mississippi
• 05.07.2026 - SIR 2026: Nationwide Analysis Finds CAVT Associated with Shorter Hospital and ICU Stays, and Lower Readmissions in ALI
• 05.06.2026 - Employee Spotlight: Alyssa Parafinczuk
• 05.06.2026 - Penumbra, Inc. Reports First Quarter 2026 Financial Results
• 04.29.2026 - Case Study: Bilateral Pulmonary Thrombus Burden Rapidly Removed with Lightning Flash 3.0 While Minimizing Blood Loss
• 04.22.2026 - SIR 2026: Closing the Gap — What the STRIKE-PE Study Reveals About CAVT Outcomes in Male and Female Patients

Recent Filings

• 05.29.2026 - SD Specialized disclosure report
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.07.2026 - 8-K Current report
• 05.07.2026 - 425 Prospectuses and communications, business combinations
• 05.06.2026 - 8-K Current report
• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - ARS Annual Report to Security Holders
• 04.29.2026 - DEF 14A Other definitive proxy statements